Artiva Biotherapeutics CMO sells $5,148 in stock
Subhashis Banerjee, Artiva Biotherapeutics CMO, recently reported transactions involving the company's common stock. On August 18, 2026, Mr. Banerjee sold 429 shares of Artiva Biotherapeutics common stock for a total value of $5,148. The shares were sold at a price of $12.0 per share. The stock currently trades at $11.70, reflecting a remarkable 332% gain over the past year from its 52-week low of $2.22.
Artiva Biotherapeutics’ rheumatoid arthritis treatment efforts gain momentum
Artiva Biotherapeutics recently made significant strides in its rheumatoid arthritis treatment efforts. The company received the Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA for its AlloNK therapy in combination with rituximab, aimed at treating refractory rheumatoid arthritis. This designation allows Artiva to benefit from expedited development and review processes with the FDA. Additionally, Artiva presented encouraging clinical data at the European Alliance of Associations for Rheumatology Congress, where 71% of patients in a Phase 2a trial achieved an ACR50 response, indicating significant disease improvement.
- Cantor Fitzgerald reiterated an Overweight rating on Artiva’s stock, maintaining a price target of $40.00. The firm discussed Artiva’s safety profile, strategy, and manufacturing capabilities in a recent webinar with the company’s CEO.
- These developments highlight Artiva’s ongoing efforts and progress in the field of rheumatologic disease therapies.
